10 Critical Success Factors for Commercializing Cell & Gene Therapies

Successful CGT commercialization requires orchestration across a complex journey spanning early diagnosis, molecular testing, treatment evaluation, authorized treatment centers, manufacturing, logistics, payer negotiation, and long-term patient monitoring1

Technology education should begin three or more years before anticipated approval to build scientific credibility and shape market perceptions before payer and provider narratives become entrenched1

Commercial planning for CGTs must begin two to three years pre-launch, with infrastructure supporting real-time performance tracking and rapid course correction due to small patient populations and complex logistics1

The '3 A's' of successful CGT launches are approvability, affordability, and accessibility4

Manufacturing innovations including automation, decentralized manufacturing, and process optimization are critical to reducing costs and timelines while maintaining regulatory compliance and product quality4

Cost of goods, manufacturability, and payer-relevant outcomes data must be integrated into R&D strategy from early development stages4

Standard CGT development involves an average cost of $2.5 billion to bring treatment to market with success rates under 10%, though CGTs are three times more likely to be approved than traditional drugs5

Value-Based Contracts require long-term data collection partnerships between payers and healthcare delivery networks established early in commercialization strategy1

High-touch services addressing patient safety, access, adherence, quality of life, and product logistics are essential for successful commercialization2

As of early 2026, the FDA has approved more than 35 cell and gene therapies, with the agency implementing flexible requirements for chemistry, manufacturing and control processes to expedite product development7 10